Pathogenetic therapy of COVID-19: focus on glucocorticoids
DOI:
https://doi.org/10.22141/2224-0586.18.2.2022.1466Keywords:
COVID-19, systemic inflammatory response, pro-inflammatory cytokines, hypothalamo-pituitary-adrenal system, glucocorticoids, reviewAbstract
The problem of preventing excessive production of pro-inflammatory cytokines in the case of COVID-19 remains unresolved. The use of steroids in the treatment of coronavirus pneumonia remains controversial. To date, there is insufficient literature data for the routine use of steroids in COVID-19 intensive care programs, and this issue remains the subject of continuous research and endless debate. The review of the scientific literature focuses on one of the areas of pathogenetic therapy for COVID-19 — the prevention and elimination of hyperproduction of pro-inflammatory cytokines using glucocorticoid drugs. The review presents modern international recommendations on the use of glucocorticoid drugs in severe COVID-19, examines the pathogenetic mechanisms of their action and side effects.
Downloads
References
National Institutes of Health. COVID-19 Treatment Guidelines Corticosteroids. Accessed: 2020 Oct 17. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/.
World Health Organization. Corticosteroids for COVID-19. WHO. Accessed: 2020 Oct 17. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.